Within MCF, different technical pathways imply fundamentally different capital profiles, timelines, and risk structures. The challenge for investors is distinguishing which approaches offer credible, financeable routes to commercial deployment.

• What are realistic capital requirements and timelines from here to commercial operation for MCF approaches?
• How do break-even challenges, technology risks, and proof-point milestones compare across tokamak, stellarator and magnetic mirror approaches?
• What makes different fusion technologies more or less attractive to different investor types?
• How should investors think about diversification across fusion technologies versus concentration in one approach?
• What near-term milestones will de-risk each pathway and move investor capital from evaluation to deployment?

Participants include: